Clin2
NCT06878066Possibly a fitRecruiting

Clot-busting treatment after stroke while on Factor Xa inhibitor

StrokeStroke (in Patients With Atrial Fibrillation)Ischemic StrokeAcute Ischemic StrokeAnticoagulant TherapyFactor Xa InhibitorIntracranial HemorrhagesHemorrhagic Transformation Due to Acute Stroke

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests a clot-busting drug (thrombolysis) for people who had a stroke while on a Factor Xa inhibitor blood thinner. It aims to see if the drug can still safely break up the clot and reduce disability.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
300 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You took a Factor Xa inhibitor (like apixaban, rivaroxaban, edoxaban, or betrixaban) within the last 48 hours, or you are currently prescribed one.
  • You are having a disabling stroke and can get treatment within 4.5 hours of symptom start (or have a special MRI if you woke up with symptoms).
  • You do not have a large brain artery clot that can be removed by a procedure within 30 minutes.
  • You do not have a bleeding disorder, recent major surgery, or serious bleeding risk.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06749834Recruiting· Phase 3
Clot-busting drug after stroke in people on newer blood thinners

This trial tests whether a clot-busting medication given through a vein (intravenous thrombolysis) can safely treat acute ischemic stroke within 24 hours in people who have taken a newer oral blood thinner (NOAC) within the last 4 to 48 hours.

Hangzhou, Zhejiang
NCT06571149Recruiting· Phase 4
Blood thinners and clot-busting drugs for stroke

This trial tests whether giving a clot-dissolving medicine (alteplase or tenecteplase) is safe and effective for people who have had a stroke and are taking a blood thinner (DOAC) like apixaban or rivaroxaban. It aims to see if this treatment can still be given within a few hours of the stroke.

Eisenstadt
NCT06556446Recruiting
Clot-busting drug after stroke if on blood thinner

This study looks at whether giving a clot-busting medicine (IV thrombolysis) is safe and effective for people who have had a stroke and also recently took a direct oral anticoagulant (DOAC). If you've taken a DOAC in the last 48 hours, this trial may help doctors decide the best treatment for you.

Innsbruck
NCT07537933Not yet recruiting· Phase 3
Blood Thinner Injection During Stroke Clot Removal

This trial tests whether injecting a blood thinner called tirofiban directly into brain blood vessels during a stroke procedure helps prevent clots from forming again. If you've had a stroke caused by a large clot in your brain that was successfully removed, this study may help protect your recovery.

Jinan, Shandong
NCT07137832Recruiting· Phase 3
Testing clot-busting drug during stroke treatment for medium vessel blockages

This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.

Guangzhou, Guangdong
NCT07621796Not yet recruiting· Phase 3
Tenecteplase for Stroke Patients Taking Blood Thinners

This trial tests whether a clot-busting drug called tenecteplase works safely in people having a stroke who are already taking certain blood-thinning medications (like apixaban or rivaroxaban). The goal is to see if it can restore blood flow to the brain better than current treatments.

Neptune City, New Jersey

Hear when a new Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.